|Day Low/High||0.55 / 0.57|
|52 Wk Low/High||0.50 / 2.38|
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Advanced Bladder Cancer Who Had Failed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine
Patent Protection for RX-5902 (Supinoxin™) Extended until 2036 for Multiple Cancers including Triple Negative Breast Cancer
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Advanced Bladder Cancer Resistant to Gemcitabine who had failed on Multiple Prior Treatments
Patent Protection Extended until 2034
Patent Protection for RX-3117 Extended until 2036
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.